Literature DB >> 19362838

Design and synthesis of novel hybrid benzamide-peptide histone deacetylase inhibitors.

Fang Hu1, C James Chou, Joel M Gottesfeld.   

Abstract

We designed and synthesized a series of novel hybrid histone deacetylase inhibitors based on conjugation of benzamide-type inhibitors with either linear or cyclic peptides. Linear tetrapeptides (compounds 13 and 14), cyclic tetrapeptides (compounds 1 and 11), and heptanediamide-peptide conjugates (compounds 10, 12, 15 and 16) were synthesized through on-resin solid-phase peptide synthesis (SPPS). All compounds were found to be moderate HDAC1 and HDAC3 inhibitors, with IC(50) values ranging from 1.3 microM to 532 microM. Interestingly, compound 15 showed 19-fold selectivity for HDAC3 versus HDAC1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362838      PMCID: PMC3045849          DOI: 10.1016/j.bmcl.2009.03.085

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  27 in total

1.  Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression.

Authors:  H Y Kao; M Downes; P Ordentlich; R M Evans
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

2.  Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor.

Authors:  E Hu; Z Chen; T Fredrickson; Y Zhu; R Kirkpatrick; G F Zhang; K Johanson; C M Sung; R Liu; J Winkler
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

Review 3.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

4.  Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.

Authors:  C J Phiel; F Zhang; E Y Huang; M G Guenther; M A Lazar; P S Klein
Journal:  J Biol Chem       Date:  2001-07-25       Impact factor: 5.157

5.  Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.

Authors:  David Herman; Kai Jenssen; Ryan Burnett; Elisabetta Soragni; Susan L Perlman; Joel M Gottesfeld
Journal:  Nat Chem Biol       Date:  2006-08-20       Impact factor: 15.040

6.  Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.

Authors:  C James Chou; David Herman; Joel M Gottesfeld
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

7.  The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Paula A Desplats; Bin Tang; Elisabetta Soragni; Ryan Burnett; Fuying Gao; Kelsey M Fitzgerald; Jenna F Borok; David Herman; Daniel H Geschwind; Joel M Gottesfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-30       Impact factor: 11.205

Review 8.  Therapeutic role of sirtuins in neurodegenerative disease.

Authors:  Tiago Fleming Outeiro; Oldriska Marques; Aleksey Kazantsev
Journal:  Biochim Biophys Acta       Date:  2008-03-07

Review 9.  NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs.

Authors:  A Vaquero; R Sternglanz; D Reinberg
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

10.  Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.

Authors:  R Furumai; Y Komatsu; N Nishino; S Khochbin; M Yoshida; S Horinouchi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  8 in total

Review 1.  Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2009.

Authors:  Roland E Dolle; Bertrand Le Bourdonnec; Karin Worm; Guillermo A Morales; Craig J Thomas; Wei Zhang
Journal:  J Comb Chem       Date:  2010-10-05

2.  Vorinostat-like molecules as structural, stereochemical, and pharmacological tools.

Authors:  Stephen Hanessian; Luciana Auzzas; Andreas Larsson; Jianbin Zhang; Giuseppe Giannini; Grazia Gallo; Andrea Ciacci; Walter Cabri
Journal:  ACS Med Chem Lett       Date:  2010-03-11       Impact factor: 4.345

3.  Retinoic acid and histone deacetylases regulate epigenetic changes in embryonic stem cells.

Authors:  Alison M Urvalek; Lorraine J Gudas
Journal:  J Biol Chem       Date:  2014-05-12       Impact factor: 5.157

4.  Control of HIV latency by epigenetic and non-epigenetic mechanisms.

Authors:  Uri Mbonye; Jonathan Karn
Journal:  Curr HIV Res       Date:  2011-12-01       Impact factor: 1.581

5.  Search for the pharmacophore of histone deacetylase inhibitors using pharmacophore query and docking study.

Authors:  Atefeh Haji Agha Bozorgi; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

Review 6.  The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.

Authors:  Fangyuan Cao; Martijn R H Zwinderman; Frank J Dekker
Journal:  Molecules       Date:  2018-03-02       Impact factor: 4.411

7.  Peptide-Based 2-Aminophenylamide Probes for Targeting Endogenous Class I Histone Deacetylase Complexes.

Authors:  Julian Seidel; Tobias Meisinger; Julia Sindlinger; Paulina Pieloch; Iris Finkemeier; Dirk Schwarzer
Journal:  Chembiochem       Date:  2019-09-26       Impact factor: 3.164

8.  Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly.

Authors:  Takayoshi Suzuki; Yuki Kasuya; Yukihiro Itoh; Yosuke Ota; Peng Zhan; Kaori Asamitsu; Hidehiko Nakagawa; Takashi Okamoto; Naoki Miyata
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.